CA3244234A1 - PCLX-001 ORAL IN THE TREATMENT OF HUMAN CANCER - Google Patents
PCLX-001 ORAL IN THE TREATMENT OF HUMAN CANCERInfo
- Publication number
- CA3244234A1 CA3244234A1 CA3244234A CA3244234A CA3244234A1 CA 3244234 A1 CA3244234 A1 CA 3244234A1 CA 3244234 A CA3244234 A CA 3244234A CA 3244234 A CA3244234 A CA 3244234A CA 3244234 A1 CA3244234 A1 CA 3244234A1
- Authority
- CA
- Canada
- Prior art keywords
- pclx
- cancer
- oral dosage
- hours
- per day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316153P | 2022-03-03 | 2022-03-03 | |
| US63/316,153 | 2022-03-03 | ||
| PCT/CA2023/050281 WO2023164776A1 (en) | 2022-03-03 | 2023-03-03 | Oral pclx-001 in the treatment of human cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244234A1 true CA3244234A1 (en) | 2023-09-07 |
Family
ID=87882761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244234A Pending CA3244234A1 (en) | 2022-03-03 | 2023-03-03 | PCLX-001 ORAL IN THE TREATMENT OF HUMAN CANCER |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250161299A1 (https=) |
| EP (1) | EP4486344A4 (https=) |
| JP (1) | JP2025507923A (https=) |
| KR (1) | KR20240155234A (https=) |
| CN (1) | CN118829428A (https=) |
| AU (1) | AU2023228703A1 (https=) |
| CA (1) | CA3244234A1 (https=) |
| IL (1) | IL314984A (https=) |
| MX (1) | MX2024010584A (https=) |
| WO (1) | WO2023164776A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025050208A1 (en) * | 2023-09-05 | 2025-03-13 | Pacylex Pharmaceuticals Inc. | Oral pclx-001 in the treatment of human cancer |
| CN120361006A (zh) * | 2025-05-19 | 2025-07-25 | 上海交通大学医学院附属第九人民医院 | Nmt1抑制剂及其在制备实体瘤治疗药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110974967B (zh) * | 2012-10-30 | 2023-11-07 | 厄尔莱克斯制药公司 | 合成致死与癌症的治疗 |
| JP7539760B2 (ja) * | 2015-07-17 | 2024-08-26 | パシレックス・ファーマシューティカルズ・インコーポレイテッド | Ｎｍｔ２の後成的なサイレンシング |
| GB201820660D0 (en) * | 2018-12-19 | 2019-01-30 | Imperial Innovations Ltd | Cancer treatments |
| MX2023004341A (es) * | 2020-10-20 | 2023-05-24 | Pacylex Pharmaceuticals Inc | Uso de inhibidores de n-miristoil transferasa (nmt) en el tratamiento del cancer, trastornos autoinmunes y trastornos inflamatorios. |
-
2023
- 2023-03-03 KR KR1020247029643A patent/KR20240155234A/ko active Pending
- 2023-03-03 CA CA3244234A patent/CA3244234A1/en active Pending
- 2023-03-03 AU AU2023228703A patent/AU2023228703A1/en active Pending
- 2023-03-03 CN CN202380025222.6A patent/CN118829428A/zh active Pending
- 2023-03-03 US US18/841,472 patent/US20250161299A1/en active Pending
- 2023-03-03 EP EP23762647.8A patent/EP4486344A4/en active Pending
- 2023-03-03 WO PCT/CA2023/050281 patent/WO2023164776A1/en not_active Ceased
- 2023-03-03 MX MX2024010584A patent/MX2024010584A/es unknown
- 2023-03-03 IL IL314984A patent/IL314984A/en unknown
- 2023-03-03 JP JP2024552265A patent/JP2025507923A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025507923A (ja) | 2025-03-21 |
| CN118829428A (zh) | 2024-10-22 |
| WO2023164776A1 (en) | 2023-09-07 |
| MX2024010584A (es) | 2024-09-06 |
| KR20240155234A (ko) | 2024-10-28 |
| AU2023228703A1 (en) | 2024-09-12 |
| EP4486344A4 (en) | 2026-03-04 |
| IL314984A (en) | 2024-10-01 |
| EP4486344A1 (en) | 2025-01-08 |
| US20250161299A1 (en) | 2025-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI831916B (zh) | 包含tno155和瑞博西尼之藥物組合 | |
| CN112566660B (zh) | 具有braf突变的癌症的组合疗法 | |
| US20250161299A1 (en) | Oral pclx-001 in the treatment of human cancer | |
| US11957662B2 (en) | Treatments with nirogacestat | |
| WO2022271923A1 (en) | Erk1/2 and kras g12c inhibitors combination therapy | |
| US12213958B2 (en) | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms | |
| AU2018285823A1 (en) | Tinostamustine for use in treating ovarian cancer | |
| US11951096B2 (en) | Treatments with nirogacestat | |
| KR20140040728A (ko) | Pi3k 억제제 화합물을 사용한 중피종 치료 방법 | |
| US20230119759A1 (en) | Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound | |
| CA3123510A1 (en) | Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer | |
| WO2025050208A1 (en) | Oral pclx-001 in the treatment of human cancer | |
| US20250025446A1 (en) | Treatments with nirogacestat | |
| US12186305B2 (en) | Treatments with nirogacestat | |
| WO2014031856A1 (en) | Combination therapy using pi3 kinase and braf inhibitors | |
| RU2813111C2 (ru) | Фармацевтическая комбинация, содержащая tno155 и рибоциклиб | |
| WO2026019787A1 (en) | Methods of treating merkel cell carcinoma with tryptophan hydroxylase inhibitors | |
| WO2025188928A1 (en) | Administration of low-dose thiostrepton for treating cancer | |
| WO2022271939A1 (en) | Erk1/2 and cdk4/6 inhibitors combination therapy | |
| TW202444376A (zh) | 治療癌症之方法 | |
| HK1190636A (en) | Methods of treating mesothelioma with a pi3k inhibitor compound | |
| JP2000503994A (ja) | 結腸腫瘍を抑制する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240814 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240819 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240819 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240819 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250228 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250228 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250228 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260223 |